Tapering Qelbree and Transitioning to Methylphenidate

Rationale for Medication Switching

Viloxazine does not require tapering because it is not associated with withdrawal symptoms or rebound hypertension upon cessation, unlike alpha-2 agonists, which must be tapered to avoid rebound hypertension, as noted by the American Academy of Pediatrics 1

The American Academy of Child and Adolescent Psychiatry recommends beginning with long-acting methylphenidate formulations, such as OROS-methylphenidate/Concerta 18-36 mg once daily in the morning, rather than immediate-release, as long-acting formulations provide superior adherence, lower rebound risk, and 12-hour coverage 3, 2
For adults, methylphenidate dosing typically ranges from 20-60 mg daily, with most patients requiring 20-30 mg daily for optimal effect, according to the American Psychiatric Association 3

Assess response after 1 week at the starting dose, as stimulants work rapidly, unlike viloxazine which requires weeks to reach full effect, as recommended by the American Academy of Child and Adolescent Psychiatry 3, 4
Titrate upward weekly by 18 mg increments if response is inadequate, up to a maximum of 54-72 mg daily for OROS formulations, as suggested by the American Psychiatric Association 3, 2
Methylphenidate demonstrates 78% response rates when dosed appropriately at approximately 1 mg/kg total daily dose, according to the American Academy of Child and Adolescent Psychiatry 3

Monitor for ADHD symptom control using standardized rating scales, as the rapid onset of stimulants allows quick assessment of efficacy, as recommended by the American Academy of Child and Adolescent Psychiatry 3, 4
Check blood pressure and heart rate at baseline and after each dose adjustment, as stimulants can elevate cardiovascular parameters, according to the American Heart Association 3
Assess for sleep disturbances, as methylphenidate causes less insomnia than amphetamines but still requires monitoring, particularly if doses are given after 2:00 PM, as noted by the American Academy of Sleep Medicine 2
Track appetite and weight changes, as appetite suppression is a common stimulant side effect, according to the American Psychiatric Association 3

Consider atomoxetine (60-100 mg daily) if active substance abuse, uncontrolled hypertension, or symptomatic cardiovascular disease is present, as recommended by the American Psychiatric Association 3
Alpha-2 agonists (guanfacine 1-4 mg or clonidine) can be used if tics, severe anxiety, or sleep disturbances complicate stimulant use, according to the American Academy of Child and Adolescent Psychiatry 3
Trial amphetamine-based stimulants (Adderall, Vyvanse) before abandoning stimulants entirely, as 40% of patients respond to only one stimulant class, as suggested by the American Academy of Child and Adolescent Psychiatry 3
Consider adjunctive therapy with extended-release guanfacine or clonidine if stimulant monotherapy is insufficient, as recommended by the American Academy of Pediatrics and the American Psychiatric Association 1, 3